Trial Profile
Observational Study to Evaluate the Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Autologous stem cell therapy (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors EHL Bio
- 14 Feb 2023 Status changed from active, no longer recruiting to completed.
- 10 Jan 2022 Planned primary completion date changed from 17 Aug 2021 to 16 Aug 2022.
- 25 Dec 2019 Planned End Date changed from 19 Sep 2022 to 16 Aug 2022.